Mounjaro was developed by the pharmaceutical company Eli Lilly and first approved for medical use in 2022. It’s based on years of research into dual hormone therapies that target both GIP and GLP-1 pathways. Its effectiveness has since been demonstrated in large international trials, helping establish it as a new generation of treatment for type 2 diabetes and weight management. How Mounjaro began The story of Mounjaro started in the early 2010s, when researchers explored way

Any time of day works — morning or evening — because the weekly dose is designed to be flexible. Pick a time you can stick to, keep it...

Yes. You can change to a new weekly day as long as at least 3 full days have passed since your last injection. Once you switch, keep using the new day each week. If you’re unsure about the timing, ask your clinic to help you plan the change. Why flexibility exists Wegovy is designed as a once-weekly injection, and the dosing rules were created with real life in mind. Few people manage a routine that never changes. Work patterns, holidays, travel, or family events can all inte

Yes. You can change to a new weekly day as long as at least 3 full days have passed since your last injection. Once you switch, keep...

Any time of day works — morning or evening — because the weekly dose is designed to be flexible. Pick a time you can stick to, keep it the same each week, and set a reminder so doses aren’t missed. If your routine changes (shift work, travel), you can move the time as long as your weekly schedule stays consistent. A flexible schedule Wegovy is designed as a once-weekly injection, and its long half-life means the exact time of day does not affect how well it works. Whether you

The vast majority of patients on Mounjaro currently pay for it privately but some patients can get it on the NHS...

The vast majority of patients on Mounjaro currently pay for it privately but some patients can get it on the NHS...

Yes, Wegovy and metformin are often used together in people with type 2 diabetes, and no special dose adjustment is typically required. They work differently: Wegovy (a GLP-1 receptor agonist) reduces appetite, slows stomach emptying, and boosts insulin release, while metformin mainly reduces glucose production in the liver and improves insulin sensitivity. Why combination treatment is common Many people living with type 2 diabetes require more than one medicine to manage blo

In major STEP trials, Wegovy led to about 15% weight loss over 68 weeks. Contrave (called Mysimba in the UK) generally achieves around...

Yes, Wegovy and metformin are often used together in people with type 2 diabetes, and no special dose adjustment is typically required....

In major STEP trials, Wegovy led to about 15% weight loss over 68 weeks. Contrave (called Mysimba in the UK) generally achieves around 6–9% across pivotal studies. This means semaglutide tends to provide greater weight reduction than naltrexone/bupropion combinations. Two very different medicines Although both Wegovy and Contrave are used for weight management, they belong to very different drug families and work in different ways. Wegovy contains semaglutide, a GLP-1 recepto

Wegovy contains semaglutide at a higher dose and is licensed for weight management, while Trulicity (dulaglutide) is prescribed for type 2 diabetes. Weight changes with dulaglutide are usually modest compared with the significant reductions seen in trials of semaglutide for obesity. Different active ingredients and purposes The first key difference is that Wegovy and Trulicity contain different GLP-1 receptor agonists. Wegovy delivers semaglutide at doses up to 2.4 mg weekly,

Wegovy contains semaglutide at a higher dose and is licensed for weight management, while Trulicity (dulaglutide) is prescribed for type...

Standard UK instructions start at 0.25 mg once weekly and step up gradually to improve comfort and reduce tummy side effects. Starting at...

Standard UK instructions start at 0.25 mg once weekly and step up gradually to improve comfort and reduce tummy side effects. Starting at 0.5 mg is not the routine plan and tends to increase nausea for first-time GLP-1 users. If you’ve previously tolerated a GLP-1, your prescriber will still weigh the pros and cons before deviating from the usual start. Why titration matters Wegovy contains semaglutide, a GLP-1 receptor agonist that acts on appetite control centres in the bra

Recommended sites are the abdomen, thigh, or upper arm. Rotate sites each week to reduce local irritation, and avoid areas that are...

Recommended sites are the abdomen, thigh, or upper arm. Rotate sites each week to reduce local irritation, and avoid areas that are tender, bruised, scarred, or inflamed. If a spot stings or looks red after, switch to a different area next time and mention it at your review. NHS training stresses that choosing the right location improves comfort and consistency over the long term. Why injection site matters Wegovy is given subcutaneously, meaning the medicine needs to sit in

Clinical trials included adults up to their mid-70s, and weight loss benefits were seen across age groups. There’s limited evidence...

Many people on Wegovy report fewer food cravings and better control over eating, which can reduce stress around meals. Other drugs like Mysimba may also affect mood and cravings, but semaglutide’s impact on appetite tends to have the strongest indirect psychological benefit. Why psychological effects matter Weight management is never only about the body. Emotional wellbeing, self-confidence, and the stress of managing food choices all play a big role in how people experience

Clinical trials included adults up to their mid-70s, and weight loss benefits were seen across age groups. There’s limited evidence directly comparing older versus younger adults, but no major differences in effectiveness have been noted, though older people may be more sensitive to side effects. Who was included in the trials The large clinical trials of semaglutide, such as the STEP programme, included adults with overweight or obesity up to about 75 years old. This means w